Abstract:Drug design is usually understood as “an inventive process of finding new medications based on the knowledge of the biological target” – according to the Wikipedia definition – where “drug” is usually defined as a relatively small organic ligand binding to a biomolecule to either inhibit or promote its activity. [1] Methods of thus-defined drug design are well established in the early stages of drug discovery and focus mainly on identifying new chemical entities (NCEs) – molecules with desired biological activity. Along with activity, however, drugs must possess acceptable ADMET (Absorption, Distribution, Metabolism, Elimination, and Toxicity) properties. Although a few recent trends push ADMET optimization into drug design, these properties are still largely neglected until the lead optimization phase occurring later in drug discovery when the available chemical space is already narrowed by affinity and selectivity concerns. Usually one group of drug discovery researchers hands out lead molecules to a separate group of drug development scientists: “Our job is done, here are the active molecules. Now you worry about their other properties.” This separation could, and often does, lead to frustrating failures where all the lead compounds may, for example, turn out to be insoluble in water, impermeable via the intended route of administration, unacceptably metabolized by enzymes common to co-medications, or produce unacceptable adverse effects. All the effort and cost of discovering them would then be wasted. Authors of this article strongly believe in “ADMET design” – a paradigm where ADMET properties are included in the earliest stages of drug discovery and treated on equal footing with biological efficacy. This multidimensional search and optimization should be a normal function of the team of discovery chemists and other pharmaceutical scientists. The difficulty is that humans are not well-adapted to thinking in more than a few dimensions at once. In silico approaches are the solution as they facilitate integration of multiple variables and the most efficient use of experimental data. In the following sections we focus on machine learning approaches, such as Artificial Neural Networks (ANN) [2] or Support Vector Machines (SVM) [3], to QSAR/QSPR modeling [4] of ADMET properties. In QSAR/QSPR, chemical structures are encoded by calculated values of molecular descriptors serving as inputs to mathematical predictive models. ANN models, in particular, have been determined to be superior predictors over other methods. [5] Training several ANN or SVM and taking an arithmetic average of their outputs as the final answer usually enhances accuracy of prediction and is known as ANN Ensemble (ANNE) or SVM Ensemble (SVME) approaches. [6] Some researchers regard these techniques as “black boxes” meaning that although ANNE or SVME models can produce numerical outputs, their internal complexity precludes any descriptive interpretation of these results. Contrary to these stereotypical beliefs, predictive mathematical models of this type are quite interpretable and thus amenable to a direct use in drug design. We demonstrate this claim on specific examples.

Extracting medicinal chemistry intuition via preference machine learning

Harnessing Medicinal Chemical Intuition from Collective Intelligence

Adapting Deep Learning QSPR Models to Specific Drug Discovery Projects

Machine Learning for Fast, Quantum Mechanics-Based Approximation of Drug Lipophilicity

Machine Learning Small Molecule Properties in Drug Discovery

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

Busting the Black Box Myth: Designing out Unwanted ADMET Properties with Machine Learning Approaches

A deep-learning view of chemical space designed to facilitate drug discovery

Machine learning-aided generative molecular design

SynthFormer: Equivariant Pharmacophore-based Generation of Molecules for Ligand-Based Drug Design

Controlled exploration of chemical space by machine learning of coarse-grained representations

A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery

A decision theoretic approach to model evaluation in computational drug discovery

Synergizing Chemical Structures and Bioassay Descriptions for Enhanced Molecular Property Prediction in Drug Discovery

Human-in-the-loop assisted de novo molecular design

Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis

Geometric deep learning-guided Suzuki reaction conditions assessment for applications in medicinal chemistry

Artificial intelligence in multi-objective drug design

Evolving and Nano Data Enabled Machine Intelligence for Chemical Reaction Optimization

A Zero-Shot Single-point Molecule Optimization Model: Mimicking Medicinal Chemists’ Expertise

From Intuition to AI: Evolution of Small Molecule Representations in Drug Discovery.